Summary Summary Bipolar disorder is
Bipolar disorder is associated with increased risk for associated with increased risk for dementia.We compared the prevalence of dementia.We compared the prevalence of Alzheimer's disease between 66 elderly Alzheimer's disease between 66 elderly euthymic patients with bipolar disorder euthymic patients with bipolar disorder who were on chronic lithium therapy and who were on chronic lithium therapy and 48 similar patients without recent lithium 48 similar patients without recent lithium therapy.The prevalence of dementia in the therapy.The prevalence of dementia in the whole sample was19% whole sample was19% v.
v. 7% in an age-7% in an agecomparable population. Alzheimer's comparable population. Alzheimer's disease was diagnosed in 3 patients (5%) disease was diagnosed in 3 patients (5%) on lithium and in16 patients (33%) who on lithium and in16 patients (33%) who were not on lithium ( were not on lithium (P P5 50.001).Our case0.001).Our caseĉ ontrol data suggestthatlithiumtreatment control data suggestthatlithiumtreatment reduced the prevalence of Alzheimer's reduced the prevalence of Alzheimer's disease in patients with bipolar disorder to disease in patients with bipolar disorder to levels in the general elderly population. levels in the general elderly population. This is in accordance with reports that This is in accordance with reports that lithium inhibits crucial processes in the lithium inhibits crucial processes in the pathogenesis of Alzheimer's disease. pathogenesis of Alzheimer's disease.
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At therapeutic concentrations, lithium inhiAt therapeutic concentrations, lithium inhibits glycogen synthase kinase-3, a key bits glycogen synthase kinase-3, a key enzyme in the metabolism of amyloid enzyme in the metabolism of amyloid precursor protein and the phosphorylation precursor protein and the phosphorylation of tau protein (Klein & Melton, 1996; of tau protein (Klein & Melton, 1996; Lovestone Lovestone et al et al, 1999) which are critical , 1999) which are critical steps in the formation of neuritic plaques steps in the formation of neuritic plaques and neurofibrillary tangles, the pathologiand neurofibrillary tangles, the pathological hallmarks of Alzheimer's disease. cal hallmarks of Alzheimer's disease. Therefore, we examined whether exposure Therefore, we examined whether exposure to chronic lithium treatment might protect to chronic lithium treatment might protect elderly patients with bipolar disorder elderly patients with bipolar disorder against Alzheimer's disease. against Alzheimer's disease.
METHOD METHOD
Patients were recruited at the Institute of Patients were recruited at the Institute of Psychiatry, University of Sao Paulo (which Psychiatry, University of Sã o Paulo (which granted ethical approval for the study as a granted ethical approval for the study as a whole) and whole) and Santa Casa Medical School, Santa Casa Medical School, Brazil. Inclusion Brazil. Inclusion criteria were: a DSM-IV criteria were: a DSM-IV diagnosis of bipolar disorder (American diagnosis of bipolar disorder (American Psychiatric Association, 1994); 60 years of Psychiatric Association, 1994); 60 years of age or more; continuous treatment for biage or more; continuous treatment for bipolar disorder for at least the previous 6 polar disorder for at least the previous 6 months; and euthymia in the past month months; and euthymia in the past month (scores on the Hamilton Rating Scale for (scores on the Hamilton Rating Scale for Depression (Hamilton, 1960) , and the Depression (Hamilton, 1960) , and the Young Mania Rating Scale (Young Young Mania Rating Scale (Young et al et al, , 1978) of less than 8 and 5 respectively). 1978) of less than 8 and 5 respectively). Exclusion criteria were: electroconvulsive Exclusion criteria were: electroconvulsive therapy in the previous 6 months; acute therapy in the previous 6 months; acute physical illness; organic brain syndromes; physical illness; organic brain syndromes; and comorbidity with other major psychiatric and comorbidity with other major psychiatric syndromes. Informed consent was obtained syndromes. Informed consent was obtained from patients and a first-degree relative. from patients and a first-degree relative.
Through hospital chart review we Through hospital chart review we detected 184 patients who fulfilled the first detected 184 patients who fulfilled the first three criteria. Twenty-seven patients could three criteria. Twenty-seven patients could not be located, 10 had died and 12 refused not be located, 10 had died and 12 refused to participate; 17 patients were excluded to participate; 17 patients were excluded for not being euthymic or meeting exclufor not being euthymic or meeting exclusion criteria. Thus, 118 patients with bision criteria. Thus, 118 patients with bipolar disorder (64%; 37 male, 81 female; polar disorder (64%; 37 male, 81 female; mean age 68.2 years, s. The prevalence of Alzheimer's disease The prevalence of Alzheimer's disease was 5% in the group on continuous lithium was 5% in the group on continuous lithium treatment (3 out of 66 patients) and 33% treatment (3 out of 66 patients) and 33% (16 out of 48 patients) in the group without (16 out of 48 patients) in the group without recent lithium therapy ( recent lithium therapy (P P5 50.001). The pre-0.001). The prevalence of mild cognitive impairment was valence of mild cognitive impairment was 20% and 25% respectively ( 20% and 25% respectively (P P5 50.10). Cog-0.10). Cognitive assessments of the 33 patients who nitive assessments of the 33 patients who had been treated with lithium in the past had been treated with lithium in the past were: normal function, 14 patients (42%), were: normal function, 14 patients (42%), mild cognitive impairment, 9 patients mild cognitive impairment, 9 patients (27%), and Alzheimer's disease, 10 patients (27%), and Alzheimer's disease, 10 patients (30%); this was very similar to assessments (30%); this was very similar to assessments of the remaining 15 patients in the group of the remaining 15 patients in the group who had never used lithium (40%, 20% who had never used lithium (40%, 20% and 40% respectively, and 40% respectively, P P¼0.77). 0.77). Within the group that had received conWithin the group that had received continuous lithium therapy for the past 6 tinuous lithium therapy for the past 6 months, months, there were no differences according to cogthere were no differences according to cognitive function in the mean daily dose and nitive function in the mean daily dose and mean mean serum levels of lithium (0. P¼0.002). 0.002). Consequently patients with Alzheimer's disConsequently patients with Alzheimer's disease also had a higher duration of bipolar ease also had a higher duration of bipolar disorder ( disorder (P P¼0.015) and more previous 0.015) and more previous depressive episodes ( depressive episodes (P P¼0.030) than those 0.030) than those 3 5 9 3 5 9
Statistical analysis Statistical analysis
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( 2 0 0 7 ) , 1 9 0 , 3 5 9^3 6 0 . d o i : 1 0 .11 9 2 / b j p . b p .1 0 6 . 0 2 9 8 6 8 ( 2 0 0 7 ) , 1 9 0 , 3 5 9^3 6 0 . d o i : 1 0 .11 9 2 / b j p . b p .1 0 6 . 0 2 9 8 6 8 0.079; 95% CI 0.020-0.321, 0.020-0.321, P P5 5 0.001). 0.001). When we excluded patients with AlzWhen we excluded patients with Alzheimer's disease from the analysis, no negaheimer's disease from the analysis, no negative effects of long-term lithium treatment tive effects of long-term lithium treatment on cognition were observed, as no differon cognition were observed, as no differences were found between the lithium and ences were found between the lithium and the comparison groups in the extensive the comparison groups in the extensive assessment of their neuropsychological assessment of their neuropsychological performance (data available on request). performance (data available on request).
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DISCUSSION DISCUSSION
In the present cross-sectional study of elderly In the present cross-sectional study of elderly patients with bipolar disorder, the prevalence patients with bipolar disorder, the prevalence of dementia was 19%, which is almost three of dementia was 19%, which is almost three times that expected in the elderly Brazilian times that expected in the elderly Brazilian population (7%; Herrera population (7%; Herrera et al et al, 2002) . This , 2002). This prevalence is similar to that in other studies prevalence is similar to that in other studies which report an increased risk for dementia which report an increased risk for dementia in patients with affective disorders and that in patients with affective disorders and that this risk increases with the number and durathis risk increases with the number and duration of previous affective episodes (Kessing tion of previous affective episodes (Kessing & Nilsson, 2003; Thompson & Nilsson, 2003; Thompson et al, et al, 2005) . 2005). In our study, only patients in the group In our study, only patients in the group without recent continuous lithium treatwithout recent continuous lithium treatment showed an increased prevalence of ment showed an increased prevalence of Alzheimer's disease (33%) and a trend toAlzheimer's disease (33%) and a trend toward increased mild cognitive impairment, ward increased mild cognitive impairment, which is a risk factor for Alzheimer's diswhich is a risk factor for Alzheimer's disease (Petersen, 2004) . Conversely, the preease (Petersen, 2004) . Conversely, the prevalence of Alzheimer's disease in the valence of Alzheimer's disease in the lithium group (5%) was similar to that lithium group (5%) was similar to that reported in the elderly general population reported in the elderly general population in Brazil. These findings suggest that in Brazil. These findings suggest that lithium treatment might reduce the risk of lithium treatment might reduce the risk of dementia in patients with bipolar disorder. dementia in patients with bipolar disorder. The mechanisms by which lithium might The mechanisms by which lithium might exert this effect need clarification. Because exert this effect need clarification. Because the risk for dementia may increase with the risk for dementia may increase with the number of previous affective episodes, the number of previous affective episodes, lithium might protect against dementia by lithium might protect against dementia by reducing the lifetime number of affective rereducing the lifetime number of affective relapses. This, however, does not hold true in lapses. This, however, does not hold true in our sample, because the differences between our sample, because the differences between the lithium and the non-lithium groups rethe lithium and the non-lithium groups regarding the number of previous depressive garding the number of previous depressive and manic episodes were not significant (deand manic episodes were not significant (depression: 10.4 , 1975) . Moreover, the mean duration of bi-1975) . Moreover, the mean duration of bipolar disorder in our sample was more than polar disorder in our sample was more than 25 years. Even our patients with cognitive 25 years. Even our patients with cognitive impairment who were taking lithium had impairment who were taking lithium had taken it continuously for the past 6 years. taken it continuously for the past 6 years. We feel therefore that the decision to preWe feel therefore that the decision to prescribe lithium was based on the clinical rescribe lithium was based on the clinical response and thus was independent of the sponse and thus was independent of the cognitive status of our patients, and an cognitive status of our patients, and an a a priori priori selection seems unlikely. selection seems unlikely. It thus seems possible that a protective It thus seems possible that a protective effect of lithium against Alzheimer's disease effect of lithium against Alzheimer's disease in patients with bipolar disorder might be a in patients with bipolar disorder might be a result of its intrinsic biological properties in result of its intrinsic biological properties in the brain. Preliminary data from our the brain. Preliminary data from our laboratory indicate that lithium inhibits laboratory indicate that lithium inhibits the transcription of the glycogen synthase the transcription of the glycogen synthase kinase-3 gene. Through this pathway kinase-3 gene. Through this pathway lithium may inhibit crucial processes in lithium may inhibit crucial processes in the pathogenesis of disease, such as the the pathogenesis of disease, such as the overproduction of amyloidoverproduction of amyloid-b b and tau hyperand tau hyperphosphorylation (Klein & Melton, 1996) . phosphorylation (Klein & Melton, 1996) .
